Orbis Medicines

A new era for oral macrocycle drug discovery

Copenhagen, Denmark · Founded 2024 · $93.0M raised

Headquarters
Copenhagen
Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$93.0M
Last Round
$93.0M Series BJan 2025
Rounds
1

About

Orbis Medicines is pioneering a new era for oral macrocycle drug discovery using its nGen platform, which systematically designs and tests macrocyclic compounds called nCycles optimized for oral bioavailability and membrane permeability. The company's pipeline targets diseases historically treated with injectable biologics, aiming to provide accessible oral alternatives. Orbis combines high-throughput synthesis, proprietary DNA-encoded libraries of nearly 100 billion compounds, and deep learning to accelerate macrocycle medicine.

Summary

Orbis Medicines is a Biotech company based in Copenhagen, Denmark, founded in 2024. It has raised $93.0M in total across 1 round, most recently a $93.0M Series B round in Jan 2025.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJan 2025
$93.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Orbis Medicines on Indexed.vc
<a href="https://indexed.vc/companies/orbis-medicines"><img src="https://indexed.vc/api/badge/company/orbis-medicines" alt="Orbis Medicines on Indexed.vc" width="260" height="76" /></a>